LENZ Therapeutics, Inc. (LENZ) Financial Statements
Industry: Biological Products, (No Diagnostic Substances)
In fiscal 2025, LENZ Therapeutics reported revenue of $19.1M. Net income was -$82.1M (a -430.3% net margin), or -$2.85 per diluted share. Gross margin was 97.8% and operating margin was -477.5%. Operating activities generated -$69.2M of cash, leaving -$70.0M of free cash flow. At fiscal year end, LENZ Therapeutics held $305.9M in total assets against $21.5M in total liabilities, including $25.2M of cash and equivalents.
Open the full interactive LENZ Therapeutics financials → Quarterly statements, key ratios, valuation history and price charts.
LENZ Therapeutics Key Stats
| Share Price | $3.40 |
|---|---|
| Market Cap | $106.7M |
| 52-Week Range | $3.40 – $41.85 |
| Shares Outstanding | 31.4 million (basic, 2026 Q2) |
LENZ Therapeutics Income Statement
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $19.1M |
| Cost of Goods Sold | — | — | — | — | $418,000 |
| Gross Profit | — | — | — | — | $18.7M |
| Operating Income | -$60.4M | -$105.6M | -$135.2M | -$58.6M | -$91.1M |
| Pre-Tax Income | -$70.8M | -$101.1M | -$124.7M | -$49.8M | -$81.6M |
| Income Tax | $0 | $0 | — | $1,000 | $502,000 |
| Net Income | -$70.8M | -$101.1M | -$124.7M | -$49.8M | -$82.1M |
| Diluted EPS | -$17.15 | -$12.88 | -$15.33 | -$2.34 | -$2.85 |
LENZ Therapeutics Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $12.5M | $1.6M | $1.9M | $5.5M |
| Net Income | -$16.7M | -$35.9M | -$41.5M | -$31.9M |
| Diluted EPS | -$0.59 | -$1.25 | -$1.32 | -$1.02 |
LENZ Therapeutics Balance Sheet
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Cash & Equivalents | $377.0M | $47.7M | $184.3M | $20.2M | $25.2M |
| Current Assets | $381.7M | $275.4M | $188.0M | $211.9M | $301.4M |
| Total Assets | $402.0M | $321.9M | $188.5M | $215.3M | $305.9M |
| Current Liabilities | $12.1M | $13.0M | $4.8M | $10.4M | $21.2M |
| Total Liabilities | $17.9M | $25.6M | $4.9M | $11.2M | $21.5M |
| Shareholders' Equity | $384.1M | $296.3M | $183.6M | $204.1M | $284.3M |
LENZ Therapeutics Cash Flow Statement
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Cash From Operations | -$52.9M | -$88.0M | -$90.0M | -$59.4M | -$69.2M |
| Cash From Investing | -$5.7M | -$241.9M | $226.3M | -$154.5M | -$75.7M |
| Cash From Financing | $417.5M | $597,000 | $190,000 | $199.0M | $149.7M |
| Free Cash Flow | -$58.6M | -$94.6M | -$100.9M | -$59.9M | -$70.0M |
Figures from LENZ Therapeutics' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full LENZ Therapeutics financials page for every line item.
LENZ Therapeutics Company Profile
| Ticker | LENZ |
|---|---|
| Exchange | Nasdaq |
| Industry | Biological Products, (No Diagnostic Substances) |
| Headquarters | Solana Beach, California |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company, emerging growth company |
| SEC CIK | 0001815776 |
Frequently Asked Questions
What was LENZ Therapeutics' revenue in fiscal 2025?
LENZ Therapeutics (LENZ) reported revenue of $19.1M for fiscal 2025.
What is LENZ Therapeutics' annual revenue history?
LENZ Therapeutics' annual revenue by fiscal year: 2021: $0; 2022: $0; 2023: $0; 2024: $0; 2025: $19.1M.
What was LENZ Therapeutics' net income in fiscal 2025?
LENZ Therapeutics reported net income of -$82.1M for fiscal 2025.
What was LENZ Therapeutics' earnings per share (EPS) in fiscal 2025?
LENZ Therapeutics' diluted EPS was -$2.85 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did LENZ Therapeutics generate in fiscal 2025?
LENZ Therapeutics generated -$70.0M of free cash flow in fiscal 2025.
What was LENZ Therapeutics' revenue last quarter?
In its most recent reported quarter (2026 Q2), LENZ Therapeutics reported revenue of $5.5M.
How many shares of LENZ Therapeutics are outstanding?
LENZ Therapeutics reported a weighted average of 31.4 million basic shares outstanding in 2026 Q2.
What is LENZ Therapeutics' market cap?
Based on its latest closing price, LENZ Therapeutics (LENZ) has a market capitalization of about $106.7M.
When does LENZ Therapeutics' fiscal year end?
LENZ Therapeutics' fiscal year end, as registered with the SEC, is December 31.
Where is LENZ Therapeutics headquartered?
LENZ Therapeutics lists its business address in Solana Beach, California in its SEC filings.
LENZ Therapeutics Competitors & Similar Companies
See all 136 Biological Products, (No Diagnostic Substances) companies →